GlassScriptPhysician profile
Vijay Kumar Goyal
NPI 1407966484
$4,193.45
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $1,072 · 2021: $1,440 · 2022: $411.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $930.99 | 2019-2022 | |
| Janssen Biotech, INC. | $474.73 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $357.98 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $347.94 | 2019-2022 | |
| Pfizer INC. | $288.51 | 2019-2021 | |
| Coherus Oncology, INC. | $162.15 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.72 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $101.01 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $94.09 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $91.16 | 2019-2022 | |
| Incyte Corporation | $91.09 | 2020-2022 | |
| Genzyme Corporation | $90.91 | 2019-2020 | |
| Lilly USA, LLC | $84.53 | 2019-2021 | |
| Seagen INC. | $82.78 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $74.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $62.06 | 2019-2021 | |
| Celgene Corporation | $60.98 | 2019-2021 | |
| Daiichi Sankyo INC. | $58.59 | 2020-2021 | |
| Beigene USA, INC. | $54.89 | 2021-2022 | |
| Fortovia Therapeutics, INC. | $54.85 | 2019-2020 | |
| Glaxosmithkline, LLC. | $49.58 | 2021-2022 | |
| Puma Biotechnology, INC. | $46.80 | 2021 | |
| Global Blood Therapeutics, INC. | $39.09 | 2022 | |
| Mylan Institutional INC. | $38.83 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.18 | 2019-2020 | |
| Gilead Sciences, INC. | $27.21 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.35 | 2021 | |
| Taiho Oncology, INC. | $18.20 | 2021 | |
| Genentech USA, INC. | $17.36 | 2021 | |
| Blueprint Medicines Corporation | $14.82 | 2022 | |
| Morphosys, US INC. | $14.71 | 2021 | |
| Tersera Therapeutics LLC | $14.20 | 2021 | |
| Deciphera Pharmaceuticals INC. | $14.19 | 2021 | |
| Pharmacosmos Therapeutics INC. | $13.99 | 2021 | |
| Biogen, INC. | $13.70 | 2021 | |
| Servier Pharmaceuticals LLC | $12.29 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.